Brexpiprazole NDC 27241-207

NDC codes

FDA NDC Directory

Product NDC (as listed)27241-207Labeler and product segments. Claims need a package NDC.

Product NDC at billing width27241-0207Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
27241-207-30	27241020730	30 TABLET in 1 BOTTLE (27241-207-30)Marketed from Feb 3, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Brexpiprazole
Generic name (nonproprietary): brexpiprazole
Active ingredients: Brexpiprazole — 2 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Ajanta Pharma USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 213718
Marketing start: Feb 3, 2023
Listing expires: Dec 31, 2026
Identifiers: Product ID 27241-207_430dc8c4-7349-42d5-9036-b0bdcc02a839SPL ID 430dc8c4-7349-42d5-9036-b0bdcc02a839SPL set ID 993b584c-7fe6-4551-899f-39146c8508acRxCUI 1658319, 1658327, 1658331, 1658335, 1658339, 1658343UNII 2J3YBM1K8CUPC 0327241205309, 0327241208300, 0327241209307, 0327241206306, 0327241207303, 0327241204302
Pharmacologic class: Atypical Antipsychotic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N427241020730 followed by a unit qualifier and the quantity

Package 27241-0207-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 13, 2022. This label includes a boxed warning.

Indications (excerpt from the label)

Brexpiprazole tablets are indicated for: Adjunctive treatment of major depressive disorder (MDD) in adults. Treatment of schizophrenia in adults. Brexpiprazole tablets is an atypical antipsychotic indicated for: Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults ( 1 , 14.1 ) Treatment of schizophrenia in adults

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 213718

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 213718
Product	Strength	Form · route	Labeler	Product NDC
Brexpiprazole	Brexpiprazole 1 mg/1	TabletOral	Ajanta Pharma USA Inc.	27241-206
Brexpiprazole	Brexpiprazole .25 mg/1	TabletOral	Ajanta Pharma USA Inc.	27241-204
Brexpiprazole	Brexpiprazole .5 mg/1	TabletOral	Ajanta Pharma USA Inc.	27241-205
Brexpiprazole	Brexpiprazole 3 mg/1	TabletOral	Ajanta Pharma USA Inc.	27241-208
Brexpiprazole	Brexpiprazole 4 mg/1	TabletOral	Ajanta Pharma USA Inc.	27241-209